{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-073144","form_type":"8-K","ticker":"CYTK","cik":"0001061983","company_name":"CYTOKINETICS INC","filed_at":"2023-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.083632+00:00","generated_at":"2026-06-07T06:45:00.489335+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cytokinetics announces positive Phase 3 SEQUOIA-HCM results for aficamten in obstructive HCM","bullets":["Aficamten improved exercise capacity (pVO2) vs placebo: LS mean diff 1.74 mL/kg/min (p=0.000002).","All 10 prespecified secondary endpoints met with statistical significance (p<0.0001), including KCCQ-CSS and NYHA class.","Safety profile comparable to placebo; SAEs 5.6% aficamten vs 9.3% placebo; LVEF <50% in 3.5% vs 0.7%.","No worsening heart failure or treatment interruptions due to low LVEF; full results at upcoming medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-073144","json":"https://secwatch.observer/filing/0000950170-23-073144.json","markdown":"https://secwatch.observer/filing/0000950170-23-073144.md","text":"https://secwatch.observer/filing/0000950170-23-073144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/0000950170-23-073144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/cytk-20231227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T06:45:00.489335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}